DrugPatentWatch Database Preview

Details for Patent: 8,858,996

Which drugs does patent 8,858,996 protect, and when does it expire?

Patent 8,858,996 protects VIMOVO and is included in one NDA.

This patent has thirty-five patent family members in twenty-two countries.

Summary for Patent: 8,858,996

Title:	Pharmaceutical compositions for the coordinated delivery of NSAIDS
Abstract:	The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
Inventor(s):	Plachetka; John R. (Chapel Hill, NC)
Assignee:	Pozen Inc. (Chapel Hill, NC)
Application Number:	14/244,471
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,858,996
Patent Claim Types: see list of patent claims	Composition; Dosage form; Use;

Drugs Protected by US Patent 8,858,996

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Horizon Pharma Usa	VIMOVO	esomeprazole magnesium; naproxen	TABLET, DELAYED RELEASE;ORAL	022511-002	Apr 30, 2010	AB	RX	Yes	No	➤ Sign Up	➤ Sign Up	Y			RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER	➤ Sign Up
Horizon Pharma Usa	VIMOVO	esomeprazole magnesium; naproxen	TABLET, DELAYED RELEASE;ORAL	022511-001	Apr 30, 2010	AB	RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y			RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 8,858,996

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
8,852,636	Pharmaceutical compositions for the coordinated delivery of NSAIDs	➤ Sign Up
9,161,920	Pharmaceutical compositions for the coordinated delivery of NSAIDs	➤ Sign Up
9,198,888	Pharmaceutical compositions for the coordinated delivery of NSAIDs	➤ Sign Up
6,926,907	Pharmaceutical compositions for the coordinated delivery of NSAIDs	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 8,858,996

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	474559	➤ Sign Up
Australia	2002305758	➤ Sign Up
Australia	2006235929	➤ Sign Up
Australia	2009200966	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 8,858,996

For more information try a trial or see the plans and pricing